Literature DB >> 11152688

Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production.

S Benjannet1, A Elagoz, L Wickham, M Mamarbachi, J S Munzer, A Basak, C Lazure, J A Cromlish, S Sisodia, F Checler, M Chrétien, N G Seidah.   

Abstract

Processing of the beta-amyloid precursor protein (betaAPP) by beta- and gamma-secretases generates the amyloidogenic peptide Abeta, a major factor in the etiology of Alzheimer's disease. Following the recent identification of the beta-secretase beta-amyloid-converting enzyme (BACE), we herein investigate its zymogen processing, molecular properties, and cellular trafficking. Our data show that among the proprotein convertase family members, furin is the major converting enzyme of pro-BACE into BACE within the trans-Golgi network of HK293 cells. While we demonstrate that the 24-amino acid prosegment is required for the efficient exit of pro-BACE from the endoplasmic reticulum, it may not play a strong inhibitory role since we observe that pro-BACE can produce significant quantities of the Swedish mutant betaAPP(sw) beta-secretase product C99. BACE is palmitoylated at three Cys residues within its transmembrane/cytosolic tail and is sulfated at mature N-glycosylated moieties. Data with three different antibodies show that a small fraction of membrane-bound BACE is shed into the medium and that the extent of ectodomain shedding is palmitoylation-dependent. Overexpression of full-length BACE causes a significant increase in the production of C99 and a decrease in the alpha-secretase product APPsalpha. Although there is little increase in the generation of Abeta by full-length BACE, overexpression of either a soluble form of BACE (equivalent to the shed form) or one lacking the prosegment leads to enhanced Abeta levels. These findings suggest that the shedding of BACE may play a role in the amyloidogenic processing of betaAPP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11152688     DOI: 10.1074/jbc.M009899200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  91 in total

Review 1.  Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease.

Authors:  C Dingwall
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 2.  Furin at the cutting edge: from protein traffic to embryogenesis and disease.

Authors:  Gary Thomas
Journal:  Nat Rev Mol Cell Biol       Date:  2002-10       Impact factor: 94.444

Review 3.  Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

Authors:  Xiaoyang Luo; Riqiang Yan
Journal:  Int J Clin Exp Pathol       Date:  2010-07-08

4.  Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1.

Authors:  Lujia Zhou; Lucia Chávez-Gutiérrez; Katrijn Bockstael; Ragna Sannerud; Wim Annaert; Patrick C May; Eric Karran; Bart De Strooper
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

5.  The proprotein convertase PC7: unique zymogen activation and trafficking pathways.

Authors:  Estelle Rousselet; Suzanne Benjannet; Josée Hamelin; Maryssa Canuel; Nabil G Seidah
Journal:  J Biol Chem       Date:  2010-11-12       Impact factor: 5.157

6.  Role of Ostm1 Cytosolic Complex with Kinesin 5B in Intracellular Dispersion and Trafficking.

Authors:  Subramanya N M Pandruvada; Janie Beauregard; Suzanne Benjannet; Monica Pata; Claude Lazure; Nabil G Seidah; Jean Vacher
Journal:  Mol Cell Biol       Date:  2015-11-23       Impact factor: 4.272

7.  The cysteine-rich domain of the secreted proprotein convertases PC5A and PACE4 functions as a cell surface anchor and interacts with tissue inhibitors of metalloproteinases.

Authors:  Nadia Nour; Gaétan Mayer; John S Mort; Alexandre Salvas; Majambu Mbikay; Charlotte J Morrison; Christopher M Overall; Nabil G Seidah
Journal:  Mol Biol Cell       Date:  2005-08-31       Impact factor: 4.138

8.  The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease.

Authors:  Ekaterina Rogaeva; Yan Meng; Joseph H Lee; Yongjun Gu; Toshitaka Kawarai; Fanggeng Zou; Taiichi Katayama; Clinton T Baldwin; Rong Cheng; Hiroshi Hasegawa; Fusheng Chen; Nobuto Shibata; Kathryn L Lunetta; Raphaelle Pardossi-Piquard; Christopher Bohm; Yosuke Wakutani; L Adrienne Cupples; Karen T Cuenco; Robert C Green; Lorenzo Pinessi; Innocenzo Rainero; Sandro Sorbi; Amalia Bruni; Ranjan Duara; Robert P Friedland; Rivka Inzelberg; Wolfgang Hampe; Hideaki Bujo; You-Qiang Song; Olav M Andersen; Thomas E Willnow; Neill Graff-Radford; Ronald C Petersen; Dennis Dickson; Sandy D Der; Paul E Fraser; Gerold Schmitt-Ulms; Steven Younkin; Richard Mayeux; Lindsay A Farrer; Peter St George-Hyslop
Journal:  Nat Genet       Date:  2007-01-14       Impact factor: 38.330

9.  Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts.

Authors:  Kulandaivelu S Vetrivel; Xavier Meckler; Ying Chen; Phuong D Nguyen; Nabil G Seidah; Robert Vassar; Philip C Wong; Masaki Fukata; Maria Z Kounnas; Gopal Thinakaran
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.157

Review 10.  β-Secretase: its biology as a therapeutic target in diseases.

Authors:  Haibo Wang; Rena Li; Yong Shen
Journal:  Trends Pharmacol Sci       Date:  2013-02-27       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.